Treatment of patients with multiple myeloma who are not eligible for stem cell transplantation: position statement of the myeloma foundation of Australia Medical and Scientific Advisory Group

Internal Medicine Journal
H QuachH M Prince

Abstract

Options for treatment of elderly patients with multiple myeloma have expanded substantially following the development of immunomodulatory drugs (IMiD), proteasome inhibitors and with enhancement in safety of high-dose therapy and autologous stem cell transplant (HDT + ASCT). The recognition of biological heterogeneity among elderly patients has made delivery of therapy more challenging. An individualised approach to treatment selection is recommended in an era in which highly efficacious treatment options are available for transplant-ineligible patients. Here, we summarise recommendations for patients who are considered unsuitable for HDT + ASCT, including pretreatment considerations, and induction, maintenance and supportive care therapies.

References

Nov 1, 1994·Journal of Clinical Epidemiology·M CharlsonJ Gold
Feb 22, 2002·The New England Journal of Medicine·Robert A KyleL Joseph Melton
Jun 22, 2007·The New England Journal of Medicine·Robert A KyleS Vincent Rajkumar
Aug 30, 2008·The New England Journal of Medicine·Jesús F San MiguelUNKNOWN VISTA Trial Investigators
May 20, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Cyrille HulinPhilippe Moreau
Jan 6, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antonio PalumboMario Boccadoro
Feb 5, 2011·Blood·S Vincent RajkumarUNKNOWN International Myeloma Workshop Consensus Panel 1
Oct 25, 2011·Blood·Gareth J MorganUNKNOWN National Cancer Research Institute Haematological Oncology Clinical Studies Group
May 11, 2012·The New England Journal of Medicine·Antonio PalumboUNKNOWN MM-015 Investigators
Aug 2, 2012·Nature Reviews. Clinical Oncology·S Vincent RajkumarJesus F San Miguel
Dec 13, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jesús F San MiguelPaul G Richardson
Aug 2, 2013·The New England Journal of Medicine·María-Victoria MateosJesús-F San Miguel
Sep 3, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Gareth J MorganJ Anthony Child
Dec 18, 2013·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Ayman SaadParameswaran N Hari
Dec 3, 2014·The Lancet Oncology·S Vincent RajkumarJesus F San Miguel

❮ Previous
Next ❯

Citations

Dec 10, 2014·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Benjamin W TehMonica A Slavin
Apr 24, 2019·The Medical Journal of Australia·Douglas E JoshuaJoy Ho
May 6, 2020·Internal Medicine Journal·Crystal LokeSamantha Hollingworth
Apr 1, 2021·Clinical Lymphoma, Myeloma & Leukemia·Krystal BerginUNKNOWN Australian and New Zealand Myeloma and Related Diseases Registry

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Related Papers

Annals of Oncology : Official Journal of the European Society for Medical Oncology
M MerzJens Hillengass
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
Sarah A HolsteinPhilip L McCarthy
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progrès Dans Les Recherches Sur Le Cancer
Murielle RousselMichel Attal
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Antonio PalumboMurielle Roussel
© 2022 Meta ULC. All rights reserved